Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, March 1, 2023
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
Salveen Richter Maintained (ALLO) at Strong Buy with Decreased Target to $31 on, Mar 1st, 2023
Salveen Richter of Goldman Sachs, Maintained "Allogene Therapeutics, Inc." (ALLO) at Strong Buy with Decreased Target from $35 to $31 on, Mar 1st, 2023.
Salveen has made no other calls on ALLO in the last 4 months.
There are 4 other peers that have a rating on ALLO. Out of the 4 peers that are also analyzing ALLO, 0 agree with Salveen's Rating of Hold.
These are the ratings of the 4 analyists that currently disagree with Salveen
- Brian Cheng of "JP Morgan" Upgraded from Hold to Buy and Decreased Target to $11 on, Tuesday, January 24th, 2023
- Jack Allen of "Baird" Upgraded from Hold to Buy and Held Target at $12 on, Friday, January 6th, 2023
- Jason Gerberry of "B of A Securities" Downgraded from Strong Buy to Sell and Held Target at $9 on, Monday, December 12th, 2022
- Debjit Chattopadhyay of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $29 on, Monday, November 21st, 2022
